<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58906">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02156934</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Kidney-002</org_study_id>
    <nct_id>NCT02156934</nct_id>
  </id_info>
  <brief_title>Paraurethral Transplantation of Autologous Muscle Derived Stem Cells for Treatment of Stress Incontinency</brief_title>
  <official_title>Evaluation the Effect of Autologous Muscle Derived Stem Cells Injection Into the Paraurethral Tissues for Treatment of Stress Urinary Incontinency,The Randomized Clinical Trial Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to provide confirmation of efficacy of muscle derived stem cells
      (MDCs) for the treatment of SUI in women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will be assessed the 12-month potential efficacy of autologous muscle
      derived cells as therapy for stress urinary incontinence. A total of 20 women in whom stress
      urinary incontinence had not improved underwent intra-sphincter injection of low doses
      50Ã—106 of autologous muscle derived cells, which will be derived from biopsies of their
      deltoid muscle. Assessments will be made at 1, 3, 6 and 12 months after cell injection.
      Changes in stress urinary incontinence severity were evaluated by pad test, diary of
      incontinence episodes and quality of life surveys.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>24hr voiding diary reduction</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation the 24hr voiding diary reduction by patient questionnaire 2hr pad test and cystourethroscopy and urodynamic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incontinence quality of life (I-Qol)</measure>
    <time_frame>1month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation the increasing of incontinence quality of life (I-Qol) by questionnaire form.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stress Urine Incontinency</condition>
  <arm_group>
    <arm_group_label>Muscle derived stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>paraurethral injection</intervention_name>
    <description>Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.</description>
    <arm_group_label>Muscle derived stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Stress Urinary Incontinence symptoms

          -  Urodynamic stress incontinence confirmed with multichannel urodynamic testing

          -  positive cough stress test

          -  urgency score &lt; stress score

          -  Patient's age between 40 - 65 years

          -  Desire to surgical correction of stress urinary incontinence or inadequate response
             to conservative treatment of SUI

        Exclusion Criteria:

          -  Post-void residual volume &gt;100cc

          -  Detrusor overactivity on preoperative multichannel urodynamic testing

          -  History of previous synthetic, biologic or fascial sub-urethral sling or any other
             surgery on external genitalia, bladder neck, bladder or urethra

          -  Desires future childbearing

          -  Chronic inguinal or vulvar abscess or history of Hidradenitis Suppurative

          -  History of bleeding diathesis or current anti-coagulation therapy

          -  Inguinal lymphadenopathy or inguinal/vulvar mass

          -  Current genitourinary fistula or urethral diverticulum

          -  Current sever cystocele or rectocele

          -  Active urinary infection

          -  Non-treated urge incontinency or any significant voiding dysfunction

          -  Neuromuscular disorders

          -  Uncontrolled Diabetes

          -  Reversible cause of incontinence (i.e. drug effect)

          -  Contraindications for surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Department of Regenerative Medicine &amp; Cell therapy center of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Farzaneh Sharifiaghdas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Farshad Zoharabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reza Moghadasali, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Regenerative Medicine And Royan Cell Therapy Center Royan Institute For stem Cell Biology and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <phone>(+98)23562000</phone>
    <phone_ext>516</phone_ext>
    <email>nasser.aghdami@royaninstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Arab, MD</last_name>
    <phone>(+98)23562000</phone>
    <phone_ext>414</phone_ext>
    <email>Leara91@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Aghdami, MD,PhD</last_name>
      <phone>(+98)212356000</phone>
      <phone_ext>516</phone_ext>
      <email>nasser.aghdami@royaninstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Leila Arab, MD</last_name>
      <phone>(+98)23562000</phone>
      <phone_ext>414</phone_ext>
      <email>Leara91@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Reza Moghadasali, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://Royaninstitute.org</url>
  </link>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>June 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous stress urinary incontinence muscle derived cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
